The Latest Cardiac and Vascular News
NEW HOPE, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the U.S. Food and Drug Administration (the “FDA”) granted investigational device exemption (“IDE”) approval with conditions […]
HANGZHOU, China, Aug. 6, 2023 /PRNewswire/ — Recently, Venus Medtech (Hangzhou) Inc. (“Venus Medtech”), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced the Investigational Device Exemption (IDE) full approval for its in-house developed VenusP-Valve from the U.S. Food and Drug Administration (FDA). VenusP-Valve, thus, has become the […]
INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). The study met […]
WAYNE, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, announced today that Circulation: Cardiovascular Interventions has published results from the Phase 1 portion of its Phase 1/2 clinical trial (EXACT) of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina. The findings […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced that Australia’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Australian Patent Application No. 2017277666, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular […]
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. today announced that the U.S. Food & Drug Administration granted an Investigational Device Exemption (IDE) for a U.S. clinical study of AlucentNVS, a unique light-activated, drug-coated balloon catheter technology. “AlucentNVS technology is poised to change the standard of care in treating patients undergoing life- and […]
WAYNE, Pa., Aug. 01, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+™ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a […]
PONTE VEDRA, Fla., Aug. 1, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that the Company is expanding its focus for tecarfarin to patients with implanted medical devices for heart diseases […]
SUZHOU, China, Aug. 1, 2023 /PRNewswire/ — Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced on July 31, 2023 that the first Chinese patient of the multi-center registration clinical trial for TaurusTrio™ Transcatheter Aortic Valve Replacement (TAVR) system has been enrolled. TaurusTrio™ is […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc., a leader in the development of innovative, polymer heart valves, today announced that the first 30 patients have been treated outside of the U.S., in the Indian clinical trial of the TRIA™ surgical mitral heart valve. The TRIA mitral valve is designed specifically to accommodate […]
